A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
The concept of regulatory T cell (Treg)-based immunotherapy has enormous potential for facilitating tolerance in autoimmunity and transplantation. Clinical translation of Treg cell therapy requires production processes that satisfy the rigors of Good Manufacturing Practice (GMP) standards. In this regard, we report our findings on the implementation of a robust GMP compliant process for the ex vivo expansion of clinical grade Tregs, demonstrating the feasibility of this developed process for the manufacture of a final product for clinical application. This Treg isolation procedure ensured the selection of a pure Treg population that underwent a 300-fold expansion after 36 days of culture, while maintaining a purity of more than 75% CD4 + CD25 + FOXP3 + cells and a suppressive function of above 80%. Furthermore, we report the successful cryopreservation of the final product, demonstrating the maintenance of phenotype and function. The process outlined in this manuscript has been implemented in the ONE study, a multicenter phase I/IIa clinical trial in which cellular therapy is investigated in renal transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
mTOR regulates memory CD8 T-cell differentiation
Araki, K., Turner, A. P., Shaffer, V. O., Gangappa, S., Keller, S. A., Bachmann, M. F., Larsen, C. P., & Ahmed, R. (2009) · Nature · doi:10.1038/nature08155 · Cited by 1,575 · cited 1×
“0002), supporting previous reports of the expansion in vivo of murine CD8 T cells in the presence of rapamycin (Figures 1A and 1B).(25) In contrast, the use of protocol B ensured that the percentage of CD8 cells was less than 5% at the end of the 36-day expansion period (Figures 1A and 1B).”
ResultZeiser, R., Leveson-Gower, D. B., Zambricki, E. A., Kambham, N., Beilhack, A., Loh, J., Hou, J.-Z., & Negrin, R. S. (2008) · Blood · doi:10.1182/blood-2007-06-094482 · Cited by 402 · cited 11×
“The suppressive ability of Treg lines was assessed as the percentage decrease of Teff proliferation in the presence of Tregs.”
ResultInfluentialMarek-Trzonkowska, N., Myśliwiec, M., Dobyszuk, A., Grabowska, M., Derkowska, I., Juścińska, J., Owczuk, R., Szadkowska, A., Witkowski, P., Młynarski, W., et al. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.03.016 · Cited by 384 · cited 1×
“DISCUSSION Clinical trials to date have confirmed the safety and hinted at the efficacy of Treg cell therapy in the context of bone marrow transplantation(18,19,21) and type I diabetes.(20) Based on data from such studies, there is a growing consensus that the therapeutic delivery of Tregs has great promise for immuno…”
Background
Cited by
Past, Present, and Future of Regulatory T Cell Therapy in Transplantation and Autoimmunity
Romano, M., Fanelli, G., Albany, C. J., Giganti, G., & Lombardi, G. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00043 · Cited by 512
Self-citationSawitzki, B., Harden, P. N., Reinke, P., Moreau, A., Hutchinson, J. A., Game, D. S., Tang, Q., Guinan, E. C., Battaglia, M., Burlingham, W. J., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30167-7 · Cited by 458
Self-citationAwan, M., Buriak, I., Fleck, R., Fuller, B., Goltsev, A., Kerby, J., Lowdell, M., Mericka, P., Petrenko, A., Petrenko, Y., et al. (2020) · Regenerative Medicine · doi:10.2217/rme-2019-0145 · Cited by 253
Emerging routes to the generation of functional β-cells for diabetes mellitus cell therapy
Nair, G. G., Tzanakakis, E. S., & Hebrok, M. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-0375-3 · Cited by 134
Treg cell therapy: How cell heterogeneity can make the difference
Giganti, G., Atif, M., Mohseni, Y., Mastronicola, D., Grageda, N., Povoleri, G. A., Miyara, M., & Scottà, C. (2021) · European Journal of Immunology · doi:10.1002/eji.201948131 · Cited by 82
Self-citation
Metadata
- Authors
- Fraser, H., Safinia, N., Grageda, N., Thirkell, S., Lowe, K., Fry, L. J., Scottá, C., Hope, A., Fisher, C., Hilton, R., Game, D., Harden, P., Bushell, A., Wood, K., Lechler, R. I., & Lombardi, G.
- Venue
- Molecular Therapy - Methods & Clinical Development
- Publisher
- Elsevier BV
- Published
- 2018-03
- Volume
- 8
- Pages
- 198-209
- ISSN
- 2329-0501 (ISSN-L)
- OpenAlex
- W2786610929
- Cited by
- 141
- References
- 3
- FWCI
- 4.71
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials. https://app.cochat.ai/papers/10.1016/j.omtm.2018.01.006
- The paper
- Fraser, H., Safinia, N., Grageda, N., Thirkell, S., Lowe, K., Fry, L. J., Scottá, C., Hope, A., Fisher, C., Hilton, R., Game, D., Harden, P., Bushell, A., Wood, K., Lechler, R. I., & Lombardi, G. (2018). A Rapamycin-Based GMP-Compatible Process for the Isolation and Expansion of Regulatory T Cells for Clinical Trials. Molecular Therapy - Methods & Clinical Development. https://doi.org/10.1016/j.omtm.2018.01.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.